Pharmaspectra announces investment in its future growth plan

October 07, 2019

Pharmaspectra is pleased to announce that it has partnered with Inflexion Private Equity to fund the future growth of the business.

Founded in 2005, Pharmaspectra has amassed the world’s largest most comprehensive, continuously updated and integrated online repository of disseminated medical science information. This includes over 16 million meeting abstracts, 28 million publication abstracts and 417,000 clinical trials. Pharmaspectra combines these unique data resources with industry leading disambiguation technology to provide pharmaceutical companies with the tools they need to track, understand and interpret the scientific landscape.

Pharmaspectra is recognised as providing pharmaceutical companies with the data required in order to improve a multitude of processes including global field medical team effectiveness, business development, product launch, competitive intelligence, safety monitoring and much more. Pharmaspectra is the only company that can provide a true enterprise solution to pharmaceutical companies – all therapeutic areas in all countries.

Recent developments in Pharmaspectra’s product offering have helped our customers to confirm their scientific strategy around what publications, authors, journals they should use and target and what meetings they should present at.

With Inflexion’s backing, Pharmaspectra will be expanding its global footprint in the key markets – US, Europe and Asia and accelerating new product development.

Jez Moulding, CEO at Pharmaspectra, commented: “Having created a market-leading set of enterprise solutions for the pharmaceutical industry, we see the opportunity to grow further as regulatory changes make data even more crucial for research, development and commercialisation. We believe there is further for us to go with Inflexion behind us, given their proven track record in helping businesses invest in sales and product development as well as digital enhancement.”

Simon Turner, Managing Partner at Inflexion, commented: “Pharmaspectra has amassed the world’s largest collection of global medical science and made it available to a market increasingly looking for data to inform their strategic decisions. This has made the company an indispensable partner to its clients, who stand to benefit as the business enhances its technology to provide an enlarged and improved offering.”

Pharmaspectra’s data is currently utilised by 7 of the world’s top 10 pharmaceutical companies. The firm, previously headquartered in New York, will move its headquarters to the London office while maintaining offices in the US, Switzerland, and India.

This investment was made by affiliated funds advised by Inflexion Private Equity Partners LLP.

About Inflexion

Inflexion is a mid-market private equity firm, investing in high growth, entrepreneurial businesses with ambitious management teams and working in partnership with them to accelerate growth. Inflexion’s flexible approach allows it to back both majority and minority investments, typically investing £10m to £250m of equity in each deal.

With bespoke teams and dedicated capital, Inflexion’s funds invest across all sectors from offices in London and Manchester. Inflexion helps businesses achieve the next stage of their development through international expansion, operational improvements, digital expertise, access to Inflexion’s networks and funding for acquisitions. It benefits from regional experts covering Asia, Latin America, the Middle East and North America dedicated to portfolio development, enabling investee companies to benefit from privileged access to these fast-growth markets.

In 2018, Inflexion retained a leading position in Preqin’s annual global league for consistently top performing buyout funds. It is the only UK fund to be ranked in the top 10. Inflexion has also won a number of industry accolades for its success in growing the businesses it backs.

Funds advised by Inflexion Private Equity Partners LLP have funds under management of c.£5.4bn.